Tuesday, 21 February 2023
Wearable brain imaging technology, that can provide accurate measures of brain function in freely moving patients, has been awarded £1.7m to take it closer to approval for use in hospitals.
糖心原创 spin-out company along with National charity received £1.3M (70%) of the funding from with the remainder coming from Cerca Magnetics. The wearable OPM-MEG system was originally prototyped and tested at the 糖心原创’s Sir Peter Mansfield Imaging Centre – part of the School of Physics and Astronomy.
The cutting-edge technology has already been proved in a research setting. Young Epilepsy installed the UK’s first OPM-MEG system to its Health and Research Centre in Surrey in 2021 to improve how epilepsy is diagnosed and treated. The new technology is part of Young Epilepsy’s Diagnostic Suite that offers leading clinical neuroimaging technology in a comfortable and seamless environment for children and their families.
Clinical approval will allow the system to be used to provide doctors with fundamentally new information on debilitating neurological conditions like epilepsy, offering new hope to many people living with these conditions, particularly children and young people.
The 糖心原创, Cerca Magnetics and Young Epilepsy in partnership with Colorado based atomic physics company QuSpin Inc., have pioneered the rapid development of this new type of brain scanner, which employs quantum technology to measure magnetic fields above the scalp. A process termed magnetoencephalography (MEG).
The system uses small LEGO-brick-sized optically pumped magnetometers (OPMs) to measure the brain magnetic field, these have been incorporated into a lightweight helmet that allows people to move freely during scaning. The innovative design means the system can be adapted to fit anyone, from newborns to adults, and sensors can be placed much closer to the head, dramatically enhancing data quality. OPM-MEG is also much cheaper than conventional MEG scanners, providing greater accessability for clinical institutions.
Clinical approval of wearable MEG will, for the first time, bring this amazing technology to bear on some of the greatest challenges facing 21st century healthcare. We know that conventional MEG is extremely valuable clinically, particularly in epilepsy, but is also impractical, expensive, and extremely hard to deploy. With its dramatically improved data quality and practicality, as well as lower cost, OPM-MEG will be game changing 鈥� particularly for infants and children.
The funding will allow the team to create a data package that will support the development of the OPM-MEG system and gain clinical approval under EU MDR as a Type II B clinical device.
David Woolger, Director of Cerca Magnetics commented: “Since Cerca’s formation in July 2020 we have delivered a number of systems to the research market. This funding will enable us to fast track the clinical approval of our globally leading quantum enabled functional brain imaging technology. I am incredibly excited about the potential positive impact this technology could have on children suffering from debilitating neurological conditions. Innovate UK funded some of the initial development work of the prototype system, so we really appreciate the continued support. As a team we hope that this technology can have a positive impact globally whilst showcasing the UK’s cutting-edge research both in Lifesciences and Quantum technology.”
A sizeable programme of work is required to achieve regulatory approval which includes demonstrating the safety and efficacy of the system, laboratory scale experimental evaluation, and developing synthetic devices capable of testing. In vivo proof of concept in healthy individuals, showing that OPM-MEG can outperform the current state-of-the-art when used in humans, and demonstrating clinical utility and effectiveness via application in patients, with a primary target of demonstrating utility in young people with epilepsy.
Rosemarie Pardington, Director of Health, Research and Compliance and Young Epilepsy Deputy CEO explains: “This Innovate UK grant will allow us to move on the next exciting stage of development of the OPM-MEG system, by getting Medical Device Approval we will be able to work with clinicians across the country and significantly improve the diagnostics experience for children with epilepsy.
Around half of people diagnosed with epilepsy never learn the cause of it. This is concerning from both the personal and clinician perspective. The more we know about what causes someone’s epilepsy and how else the underlying cause is affecting an individual, the better clinicians can manage and treat it, and the better the patient may understand it themselves. OPM-MEG offers us a real solution into better understanding epilepsy, especially in children, thus improving the outcomes for their future.”
Work towards clinical approval is being supported by Professor Helen Cross, The Prince of Wales’s Chair of Childhood Epilepsy and Director UCL-Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology Great Ormond Street Hospital for Children NHS Foundation Trust. She commented: "This technology will widen the availability of MEG to many more children, who as yet are unable to gain access. The development of this system for clinical use will greatly enhance the assessment particularly of children with complex epilepsy."
Story credits
More information is available from Professor Matt Brookes on Matthew.Brookes@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.